Live data · NADAC + Part D CY24 · reviewed daily

Brompheniramine Maleate, Pseudoephedrine Hydrochloride,

First FDA approval2020-06-26
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$0.068/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.068
Across all dosage forms in distribution.
Highest NADAC
$0.068
Range is tight.
Plans with PA
0 / 329
Zero PA friction across surveyed plans.

Questions a plan sponsor actually asks.

FAQPage schema5 entries indexed · 4 visible
What is Brompheniramine Maleate, Pseudoephedrine Hydrochloride, used for?

Brompheniramine Maleate, Pseudoephedrine Hydrochloride, is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Brompheniramine Maleate, Pseudoephedrine Hydrochloride,?

No. Brompheniramine Maleate, Pseudoephedrine Hydrochloride, is brand-only with no generic equivalents currently in market.

How much does my plan pay for Brompheniramine Maleate, Pseudoephedrine Hydrochloride,?

Across 329 Part D plans, Brompheniramine Maleate, Pseudoephedrine Hydrochloride, averages $0.068/unit (NADAC). Lowest available: $0.068/unit. Highest in distribution: $0.068/unit.

Is Brompheniramine Maleate, Pseudoephedrine Hydrochloride, on the FDA shortage list?

No. Brompheniramine Maleate, Pseudoephedrine Hydrochloride, is not currently on the FDA Drug Shortage Database.

1 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.